GlassScriptPhysician profile
Henry Lepore
NPI 1831185438
$8,064.98
in general payments reported to CMS, 2019-2025
46 companies · $974 in 2025
The $974 reported for 2025 was more than what 87% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $1,265 · 2021: $1,448 · 2022: $1,169 · 2023: $716 · 2024: $1,155 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,123.27 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $830.57 | 2019-2025 | Belbuca, Xtampza |
| Amgen INC. | $532.58 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $468.41 | 2020-2025 | Relistor |
| Boston Scientific Corporation | $388.74 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $315.35 | 2019-2025 | |
| Lilly USA, LLC | $305.45 | 2019-2025 | Mounjaro, Zepbound |
| Grt US Holding, INC. | $291.74 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $238.67 | 2021-2023 | Ztlido |
| Arbor Pharmaceuticals, INC. | $229.97 | 2019-2022 | |
| Valinor Pharma, LLC | $220.52 | 2023-2025 | Movantik |
| Redhill Biopharma INC. | $206.85 | 2021 | |
| Ibsa Pharma INC. | $202.80 | 2022 | |
| Horizon Therapeutics Plc | $196.38 | 2019-2020 | |
| Daiichi Sankyo INC. | $190.62 | 2019 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Lepore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.